Helus Pharma Inc.

Stage 2 · Advancing · week 11

As of Oct 22, 2026, Helus Pharma is in Stage 2, the uptrend phase, now in week 11 (since Aug 6, 2026). It closed at $10.50, 25.1% below its 52-week high and above its 200-day average, which is rising.

Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. More about the company

$10.50

-1.87% today

$767M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is HELP early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 24w

S4 21w

S4 17w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S1 3w → S2 1w → S1 1w → S4 1w → S1 1w → S2 10w → S3 8w → S4 7w → S1 7w → S4 24w → S1 9w → S4 21w → S1 11w → S4 17w → S1 7w → S2 5w → S4 17w → S1 4w → S2 11w current

Total tracked: 166 weeks across 19 stage runs.

HELP among Biotechnology65th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…65	HELPHelus Pharma Inc.	Stage 2 · wk 11	92	−19.4%

vs 52W High

-25.1%

$3.87 lo$14.02 hi

25.1% below 52W high, far from high

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 11

1w13w26w

Week 11, early Stage 2

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

37.7%

200 DMA: $7.62 · rising

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

1.16x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-19.4%

+37.8%

+82.6%

YTD

+26.8%

+73.6%

Scan Membership

Breakout Watch

Latest: 2023-10-02

4 appearances in last 60 days. First seen: 2020-12-03.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 11 · Vol 1.16x

2026-10-21S2

Wk 11 · Vol 0.48x

2026-10-20S2

Wk 11 · Vol 1.41x

2026-10-19S2

Wk 11 · Vol 0.58x

2026-10-16S2

Wk 11 · Vol 0.75x

2026-10-15S2

Wk 10 · Vol 0.87x

2026-10-14S2

Wk 10 · Vol 0.58x

2026-10-13S2

Wk 10 · Vol 1.79x

2026-10-12S2

Wk 10 · Vol 1.34x

2026-10-09S2

Wk 10 · Vol 0.96x

2026-10-08S2

Wk 9 · Vol 0.64x

2026-10-07S2

Wk 9 · Vol 0.48x

Moving averages & range

50 DMA

$12.11

200 DMA

$7.62

52W High

$14.02

52W Low

$3.87

5D Low

$10.50

Resistance levels (recent highs)

20d High

$12.70

60d High

$14.02

120d High

$14.02

250d High

$14.02

Next resistance

+21.0%

to 20d High

ROE

-86.9%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 2.7

Helus Pharma: quick answers

What stage is Helus Pharma in?

As of Oct 22, 2026, Helus Pharma (HELP) is in Stage 2, the uptrend phase. It entered Stage 2 on Aug 6, 2026 and is in week 11. What the four stages mean

Is Helus Pharma in an uptrend?

Yes. Helus Pharma is in a Stage 2 uptrend. It trades 37.7% above its 200-day average, which is rising.

How far is Helus Pharma from its 52-week high?

Helus Pharma closed at $10.50 on Oct 22, 2026, 25.1% below its 52-week high of $14.02. Its 52-week low is $3.87.

How has Helus Pharma performed over the past year?

As of Oct 22, 2026, Helus Pharma is up 73.6% over the past year and up 26.8% so far in 2026.

Which sector and industry is Helus Pharma in?

Helus Pharma is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company's preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluate HLP003 for the adjunctive treatment of major depressive disorder; and Osmind for mental health treatments. It operates in Canada, the United States, the United Kingdom, and Ireland. The company was formerly known as Cybin Inc. and changed its name to Helus Pharma Inc. in October 2026. Helus Pharma Inc. was founded in 2019 and is headquartered in Toronto, Canada.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.